title: The Avian EB66(R) Cell Line, Application to Vaccines, and Therapeutic Protein Production.
abstract: Embryonated chicken eggs and primary chicken embryo fibroblasts (CEFs) have been used for decades as a means of manufacturing human and veterinary vaccines. However, these egg and CEF-based production systems are associated with many serious limitations in terms of their regulatory acceptability, production capacity, and supply chain risks. The development of a safer, cheaper, and more efficient cell substrate for vaccine production would represent a significant business advantage for vaccine manufacturers. Building on the exceptional properties of avian embryonic stem cells, Vivalis has created a new cell substrate, the Duck EB66® cell line. This article describes how this cell substrate was derived, the manufacture and qualification of a master cell bank, and the evaluation of the cell substrate for the manufacture of vaccines and human therapeutic proteins.
authors.affiliation: Vivalis, Saint Herblain, France.
authors.forename: Stephen W
authors.initials: SW
authors.lastname: Brown
authors.forename: Majid
authors.initials: M
authors.lastname: Mehtali
mesh_terms: D000818:Animals; D002460:Cell Line; D002645:Chickens / Q000276:immunology; D004372:Ducks / Q000276:immunology; D053595:Embryonic Stem Cells / Q000276:immunology; D006801:Humans; D007252:Influenza Vaccines / Q000096:biosynthesis
chemical_list: D007252:Influenza Vaccines